Waddell & Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.52M Sell
5,432
-19
-0.3% -$19.4K 0.32% 25
2026
Q1
$5.01M Sell
5,451
-195
-3% -$198K 0.28% 26
2025
Q4
$6.07M Sell
5,646
-234
-4% -$224K 0.41% 22
2025
Q3
$4.49M Buy
5,880
+322
+6% +$240K 0.38% 26
2025
Q2
$4.33M Sell
5,558
-662
-11% -$514K 0.46% 23
2025
Q1
$5.14M Buy
6,220
+80
+1% +$66.6K 0.62% 19
2024
Q4
$4.74M Sell
6,140
-2
-0% -$1.66K 0.48% 21
2024
Q3
$5.44M Sell
6,142
-8
-0.1% -$7.19K 0.66% 20
2024
Q2
$5.57M Buy
6,150
+10
+0.2% +$8K 0.73% 19
2024
Q1
$4.78M Buy
6,140
+440
+8% +$313K 0.65% 20
2023
Q4
$3.29M Sell
5,700
-931
-14% -$543K 0.44% 24
2023
Q3
$3.56M Sell
6,631
-25
-0.4% -$12.9K 0.52% 24
2023
Q2
$3.12M Buy
6,656
+655
+11% +$275K 0.46% 23
2023
Q1
$2.06M Sell
6,001
-53
-0.9% -$17.9K 0.32% 29
2022
Q4
$2.21M Sell
6,054
-4
-0.1% -$1.42K 0.37% 28
2022
Q3
$1.96M Hold
6,058
0.38% 24
2022
Q2
$1.96M Buy
6,058
+198
+3% +$59.4K 0.4% 21
2022
Q1
$1.68M Hold
5,860
0.27% 26
2021
Q4
$1.62M Buy
5,860
+657
+13% +$167K 0.26% 26
2021
Q3
$1.2M Sell
5,203
-23,540
-82% -$5.81M 0.2% 34
2021
Q2
$1.13K Buy
+28,743
New +$5.77M 0.17% 29

Other funds holding LLY

Waddell & Associates's LLY Position: Q2 2026 in Review

Waddell & Associates reduced its Eli Lilly (LLY) stake by 0.35% in Q2 2026, selling an estimated $19.4K and leaving 5,432 shares worth $6.52M. The position accounts for 0.32% of the portfolio, ranked #25.

Waddell & Associates first reported a position in LLY in Q2 2021 and has held it in 21 quarters since. 1,692 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Waddell & Associates held 5,432 shares of Eli Lilly worth $6.52M as of Q2 2026.
  • Waddell & Associates sold 19 Eli Lilly shares in Q2 2026, an estimated $19.4K.
  • Eli Lilly made up 0.32% of Waddell & Associates's portfolio in Q2 2026, its #25 holding.
  • Waddell & Associates first reported a position in Eli Lilly in Q2 2021 and has held it in 21 quarters since.
  • 1,692 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Waddell & Associates's 13F filing for Q2 2026, filed 15 Jul 2026.